marketing@medicilon.com

ABOUT

Company Profile

Corporate Culture

Management Team

Company History

Message from the CEO

Honors and Awards

SERVICES

01 Drug Discovery

Chemistry Research Biology Research Early Pharmacokinetics

02 Pharmaceutical Research

Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center

03 Preclinical Research

Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings

PLATFORM

01 One-stop Integrated Services

Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D

02 Innovative Drug R&D Services

Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC

03 Key Technical Services for Drug R&D

Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration

04 Drug Efficacy Evaluation for Common Diseases

Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model

05 High-end Preparations Technology Platform

Skin Topical Preparation Ophthalmic drug Inhalation drug

06 Targeted Drugs R&D Services

STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service

07 Safety Assessment Lab of Process Chemistry

08 Public Services

CAREERS

Talent Development

Campus Recruitment

Recruitment

NEWS

Medicilon Events

Evolution of GLP‐1 Receptor Agonists

Name: Evolution of GLP‐1 Receptor Agonists
Uploaded: 2023-10-16
Description: Looking back, GLP-1 was found to be a cleavage product of proglucagon processing. A key breakthrough came from the discovery of exendin-4.

2023-10-16

Page View：

GLP-1 receptor agonists are now used for the treatment of type 2 diabetes and obesity. Looking back, GLP-1 was found to be a cleavage product of proglucagon processing.A key breakthrough came from the discovery of exendin-4.Exendin-4 is a peptide with agonistic properties at the GLP-1 receptor but resistance to degradation by DPP-4.Semaglutide, the first oral GLP-1 receptor agonist, marked the next milestone.

GLP-1 New Drug R&D Service
GLP-1 New Drug R&D Service
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services.